

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An immunogenic composition comprising an IL-13 element, wherein the IL-13 element is Immunogen 1 SEQ ID NO:10, that drives an immune response that recognizes human IL-13 and at least one foreign T-cell epitope.
2. (Previously Presented) An immunogenic composition as claimed in claim 1, wherein the T-cell epitope is foreign with respect to human self-proteins and IL-13 sequence from other species.
3. (Previously Presented) An immunogenic composition as claimed in claim 1, wherein the T-cell epitope is a short peptide sequence added to the IL-13 sequence.
4. (Currently Amended) An immunogenic composition as claimed in claim 3 wherein the carrier proteinT-cell epitope is selected from the group consisting of: *Haemophilus influenzae* Protein D and CPC (clyta-P2-clyta).
5. (Cancelled)
6. (Currently Amended) An immunogenic composition as claimed in claim 3, wherein at least one short T-cell epitope is added to the IL-13 sequence by an event selected from the group consisting of: an addition and a substitution.
7. (Original) An immunogenic composition as claimed in claim 6 wherein the short T-cell epitope is a promiscuous epitope.
8. (Currently Amended) An immunogenic composition as claimed in claim 7 wherein the promiscuous epitope is selected from the group consisting of: P2 and P30 from tetanus toxoid.

9-38. (Cancelled)

39. (Previously Presented) An immunogenic composition as claimed in claim 1, wherein the T-cell epitope comprises a carrier protein.

40. (Previously Presented) An immunogenic composition as claimed in claim 39, wherein the carrier protein and IL-13 element form a fusion protein.

41-42. (Cancelled)